POU1F1 gene variant linked to pituitary dwarfism in Karelian Bear Dogs

NewsGuard 100/100 Score

A study carried out at the University of Helsinki investigated pituitary dwarfism in Karelian Bear Dogs and found a link to a variant of the POU1F1 gene. The results can also help understand the gene's significance to the human pituitary gland's development and function.

The pituitary gland is a pea-sized endocrine gland composed of two structurally and functionally separate parts known as anterior and posterior lobes. The pituitary gland's anterior lobe secretes six hormones essential to growth, reproduction, and other basic physiological functions. Abnormal development of the pituitary gland, or hypopituitarism, can cause mild or complete deficiency of one or more pituitary hormones, which manifests as highly varying symptoms. Tumors mainly cause hypopituitarism in humans, but a congenital factor can also be associated with the disorder.

The POU1F1 gene regulates the development of the anterior pituitary lobe, and disruption to its function results in hormonal changes, evidenced in affected dogs as dwarfism and coat abnormalities. A gene test developed based on the findings supports diagnostics and a breeding programme to eradicate the disease from the breed.

Roughly 30 genes have been associated with inherited hypopituitarism in humans, many of which are regulator genes, which affect the development of the pituitary gland. In addition to humans, impaired pituitary function occurs in mice and dogs. In German Shepherds, hypopituitarism has previously been associated with the LHX3 gene, while in the case of Karelian Bear Dogs, the disease was described in Denmark already 45 years ago. Now, we have identified a related cause in the POU1F1 gene. This is only the second new canine model for human pituitary disease, making it quite significant."

Hannes Lohi, Professor

Samples for the study were collected from Finnish and Swedish symptomatic and asymptomatic Karelian Bear Dogs.

"We managed to get samples from a total of eight sick puppies from five different litters. The puppies were as much as 20 centimetres smaller than normal, with many of them also having a puppy-like coat or substantial hair loss. Typical of the disease, their symptoms were varied. A handful of carriers of the POU1F1 variant were also found in Lapponian Herders in an analysis encompassing more than 8,000 dogs," says Kaisa Kyöstilä, PhD, the first author of the article.

The study confirmed that the disease is inherited recessively, meaning that the affected dogs inherit the gene variant from both parents. Among Karelian Bear Dogs, only 8% of the breed carries the defect, and carriers do not develop the disease. The gene test based on the research finding can be used to identify carriers, avoid carrier-carrier combinations in breeding and eradicate this severe disease from the breed altogether.

The latest POU1F1 gene discovery is already the third disease gene described in Karelian Bear Dogs. The research group has previously described gene finds associated with dwarfism (link in Finnish only) and hypophosphatasia.

Journal reference:

Kyöstilä, K., et al. (2021) Intronic variant in POU1F1 associated with canine pituitary dwarfism. Human Genetics. doi.org/10.1007/s00439-021-02259-2.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MedStar Washington Hospital Center enrolls first U.S. patient in gene-editing therapy trial for heart disease